Reduced prostacyclin production in patients with different manifestations of ischemic heart disease
- 1 April 1982
- journal article
- research article
- Published by Elsevier BV in The American Journal of Cardiology
- Vol. 49 (5), 1146-1151
- https://doi.org/10.1016/0002-9149(82)90038-8
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- Effects of prostacyclin (PGI2), 6-oxo-PGF1 alpha and PGE2 on sympathetic nerve function in mesenteric arteries and veins of the rabbit in vitro.Hypertension, 1979
- Actions of prostacyclin (PGI2) on adrenergic neuroeffector transmission in the rabbit kidneyProstaglandins, 1979
- Prostacyclin (prostaglandin I2, PGI2) inhibits platelet adhesion and thrombus formation on subendotheliumBlood, 1979
- Effect of prostacyclin on myogenic activity and adrenergic neuroeffector interaction in canine isolated veinsProstaglandins, 1978
- Prostacyclin (PGI2) and thromboxane A2 interaction in vivo. Regulation by aspirin and relationship with anti-thrombotic therapyThrombosis Research, 1978
- Circulatory and anti-platelet effects of intravenous prostacyclin in healthy menPharmacological Research Communications, 1978
- Prostacyclin is a circulating hormoneNature, 1978
- Generation of prostacyclin by lungs in vivo and its release into the arterial circulationNature, 1978
- Reversal of platelet aggregation by prostacyclinPharmacological Research Communications, 1978
- HUMAN ARTERIAL AND VENOUS TISSUES GENERATE PROSTACYCLIN (PROSTAGLANDIN X), A POTENT INHIBITOR OF PLATELET AGGREGATIONThe Lancet, 1977